uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

uPAR PET/CT as a prognostic marker in non-small cell lung cancer.

Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by observer-blinded readings and compared to the prognostic performance of FDG PET/CT and prognostic biomarkers as uPAR.

Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.

Inclusion Criteria:

Study I

• Histologically verified NSCLC (Study I)
• Stage IV disease
• Operable disease
• The participants must be capable of understanding and giving full informed written consent

Study II

• Histologically verified MPM (Study II)
• The participants must be capable of understanding and giving full informed written consent

Study III

• Histologically verified LCNEC (Study III)
• The participants must be capable of understanding and giving full informed written consent

Exclusion Criteria:

Study I, II, III

• Pregnancy
• Lactation/breast feeding
• Treatment with neoadjuvant chemotherapy
• Weight above 140 kg
• Allergy to 68Ga-NOTA-AE105